{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:14:33Z","timestamp":1788437673865,"version":"build-2803163510"},"reference-count":126,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Pregnancy Registry for Atypical Antipsychotics"},{"DOI":"10.13039\/100000874","name":"Brain & Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JayMac Pharmaceuticals"},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National\u00a0Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SAGE Therapeutics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clp.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T04:52:48Z","timestamp":1553748768000},"page":"215-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Safety of Psychotropic Medications During Pregnancy"],"prefix":"10.1016","volume":"46","author":[{"given":"Edwin R.","family":"Raffi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Nonacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clp.2019.02.004_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.295.5.499","article-title":"Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment","volume":"295","author":"Cohen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clp.2019.02.004_bib2","unstructured":"Research C for DE and. Labeling - pregnancy and lactation labeling (Drugs) final rule. Available at: https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/labeling\/ucm093307.htm. Accessed August 6, 2018."},{"issue":"Spec No","key":"10.1016\/j.clp.2019.02.004_bib3","first-page":"1","article-title":"The expert consensus guideline series. Treatment of depression in women","author":"Altshuler","year":"2001","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clp.2019.02.004_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/pds.3462","article-title":"Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clp.2019.02.004_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1176\/ajp.153.5.592","article-title":"Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines","volume":"153","author":"Altshuler","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib6","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4088\/JCP.v67n0817","article-title":"Exposure to mirtazapine during pregnancy: a prospective comparative study of birth outcomes","volume":"67","author":"Djulus","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/070674370404901103","article-title":"Perinatal risks of untreated depression during pregnancy","volume":"49","author":"Bonari","year":"2004","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/AOG.0b013e3181ba0632","article-title":"The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists","volume":"114","author":"Yonkers","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib9","doi-asserted-by":"crossref","first-page":"1420148","DOI":"10.1016\/j.jad.2007.12.228","article-title":"Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study","volume":"110","author":"Freeman","year":"2008","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.clp.2019.02.004_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1440-1614.2002.t01-4-01015.x","article-title":"Cognitive therapy of depression. Aaon Beck, John Rush, Brian Shaw, Gary Emery. New York: Guilford, 1979","volume":"36","author":"King","year":"2002","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib11","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1176\/ajp.154.7.1028","article-title":"Interpersonal psychotherapy for depressed antepartum women: a pilot study","volume":"154","author":"Spinelli","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib12","series-title":"Interpersonal psychotherapy for depression","author":"Weissman","year":"2015"},{"key":"10.1016\/j.clp.2019.02.004_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000077745","article-title":"Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment","volume":"73","author":"Cohen","year":"2004","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.clp.2019.02.004_bib14","doi-asserted-by":"crossref","first-page":"e7085","DOI":"10.1136\/bmj.e7085","article-title":"Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study","volume":"345","author":"Bod\u00e9n","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.clp.2019.02.004_bib15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/appi.ajp.2007.06101639","article-title":"Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation","volume":"164","author":"Viguera","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib16","series-title":"Massachusetts general hospital handbook of general hospital psychiatry","article-title":"Psychiatric illness during pregnancy and the postpartum period","author":"Hogan","year":"2018"},{"key":"10.1016\/j.clp.2019.02.004_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1523-536X.1992.tb00670.x","article-title":"Treatment and outcomes of psychotic patients during pregnancy and childbirth","volume":"19","author":"Spielvogel","year":"1992","journal-title":"Birth"},{"key":"10.1016\/j.clp.2019.02.004_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jad.2011.01.003","article-title":"Generalized anxiety disorder: course and risk factors in pregnancy","volume":"131","author":"Buist","year":"2011","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.clp.2019.02.004_bib19","first-page":"266","article-title":"Panic attack-associated placental abruption: a case report","volume":"50","author":"Cohen","year":"1989","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib20","first-page":"374","article-title":"Pregnancy-related substance use in the United States during 1996-1998","volume":"101","author":"Ebrahim","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/phar.1958","article-title":"Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women","volume":"37","author":"Tran","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clp.2019.02.004_bib22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/jama.282.13.1264","article-title":"Pharmacologic treatment of depression during pregnancy","volume":"282","author":"Wisner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clp.2019.02.004_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.siny.2013.11.007","article-title":"Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy","volume":"19","author":"Ornoy","year":"2014","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.clp.2019.02.004_bib24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","article-title":"Birth outcomes in pregnant women taking fluoxetine","volume":"335","author":"Chambers","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1542\/peds.113.2.368","article-title":"Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior","volume":"113","author":"Zeskind","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.clp.2019.02.004_bib26","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1176\/appi.ajp.159.12.2055","article-title":"Outcomes of prenatal antidepressant exposure","volume":"159","author":"Simon","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib27","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1001\/jama.1993.03500170076037","article-title":"Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)","volume":"269","author":"Pastuszak","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.clp.2019.02.004_bib28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1176\/appi.ajp.159.11.1889","article-title":"Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study","volume":"159","author":"Nulman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00737-004-0057-5","article-title":"The impact of depression and fluoxetine treatment on obstetrical outcome","volume":"7","author":"Suri","year":"2004","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.clp.2019.02.004_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaac.2017.12.010","article-title":"New research: effect of time-dependent selective serotonin reuptake inhibitor antidepressants during pregnancy on behavioral, emotional, and social development in preschool-aged children","volume":"57","author":"Lupattelli","year":"2018","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.jp.7211352","article-title":"Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis","volume":"25","author":"Lattimore","year":"2005","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.clp.2019.02.004_bib32","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamapsychiatry.2016.2705","article-title":"Neurodevelopmental implications of fetal exposure to selective serotonin reuptake inhibitors and untreated maternal depression: weighing relative risks","volume":"73","author":"Cohen","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0895-4356(92)90149-H","article-title":"Self-reported depression and negative pregnancy outcomes","volume":"45","author":"Steer","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clp.2019.02.004_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.clp.2019.02.004_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn","volume":"354","author":"Chambers","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pds.1710","article-title":"Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn","volume":"18","author":"Andrade","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clp.2019.02.004_bib37","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2015.5605","article-title":"Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn","volume":"313","author":"Huybrechts","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clp.2019.02.004_bib38","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1542\/peds.2006-3037","article-title":"Risk factors for persistent pulmonary hypertension of the newborn","volume":"120","author":"Hern\u00e1ndez-D\u00edaz","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.clp.2019.02.004_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJM199701233360404","article-title":"Neurodevelopment of children exposed in utero to antidepressant drugs","volume":"336","author":"Nulman","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib40","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1176\/appi.ajp.2012.11111721","article-title":"Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression","volume":"169","author":"Nulman","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamapediatrics.2015.3356","article-title":"Antidepressant use during pregnancy and the risk of autism spectrum disorder in children","volume":"170","author":"Boukhris","year":"2016","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.clp.2019.02.004_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaac.2016.02.013","article-title":"Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national register-based study","volume":"55","author":"Malm","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/DBP.0b013e3181e5ac93","article-title":"Use of antidepressants during pregnancy and risk of attention-deficit\/hyperactivity disorder in the offspring","volume":"31","author":"Figueroa","year":"2010","journal-title":"J\u00a0Dev Behav Pediatr"},{"key":"10.1016\/j.clp.2019.02.004_bib44","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1301449","article-title":"Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism","volume":"369","author":"Hviid","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S53009","article-title":"Antidepressant exposure in pregnancy and risk of autism spectrum disorders","volume":"5","author":"S\u00f8rensen","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.clp.2019.02.004_bib46","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.4088\/JCP.17f11916","article-title":"Antidepressant exposure during pregnancy and risk of autism in the offspring: do the new studies add anything new?","volume":"78","author":"Andrade","year":"2017","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapediatrics.2017.0124","article-title":"Risk for autism spectrum disorders according to period of prenatal antidepressant exposure: a systematic review and meta-analysis","volume":"171","author":"Mezzacappa","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.clp.2019.02.004_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12884-017-1334-4","article-title":"Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study","volume":"17","author":"Heller","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.clp.2019.02.004_bib49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/AOG.0000000000001200","article-title":"Postpartum hemorrhage and use of serotonin reuptake inhibitor antidepressants in pregnancy","volume":"127","author":"Hanley","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib50","doi-asserted-by":"crossref","first-page":"f4877","DOI":"10.1136\/bmj.f4877","article-title":"Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States","volume":"347","author":"Palmsten","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clp.2019.02.004_bib51","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","article-title":"Antidepressant use in pregnancy and the risk of cardiac defects","volume":"370","author":"Huybrechts","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib52","doi-asserted-by":"crossref","first-page":"h1798","DOI":"10.1136\/bmj.h1798","article-title":"Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design","volume":"350","author":"Furu","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clp.2019.02.004_bib53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.ede.0000239581.76793.ae","article-title":"Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations","volume":"17","author":"Wogelius","year":"2006","journal-title":"Epidemiology"},{"key":"10.1016\/j.clp.2019.02.004_bib54","unstructured":"Paroxetine and pregnancy | GSK. Available at: https:\/\/www.gsk.com\/en-gb\/media\/resource-centre\/paroxetine-information\/paroxetine-and-pregnancy\/. Accessed August 22, 2018."},{"key":"10.1016\/j.clp.2019.02.004_bib55","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects","volume":"356","author":"Alwan","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib56","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":"First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects","volume":"356","author":"Louik","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib57","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1017\/S1092852900014012","article-title":"Pregnancy Exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions","volume":"13","author":"Gentile","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clp.2019.02.004_bib58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.2007.07060879","article-title":"Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy","volume":"165","author":"Einarson","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib59","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/0091270011405524","article-title":"Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study","volume":"52","author":"Klieger-Grossmann","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clp.2019.02.004_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/AOG.0b013e318220edcc","article-title":"Selective serotonin reuptake inhibitors and risk for major congenital anomalies","volume":"118","author":"Malm","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bcpt.12497","article-title":"First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review","volume":"118","author":"Lassen","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clp.2019.02.004_bib62","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1176\/appi.ajp.158.10.1728","article-title":"Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study","volume":"158","author":"Einarson","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib63","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.4088\/JCP.14f09631","article-title":"The safety of duloxetine during pregnancy and lactation","volume":"75","author":"Andrade","year":"2014","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7150\/ijms.5213","article-title":"Duloxetine and pregnancy outcomes: safety surveillance findings","volume":"10","author":"Hoog","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clp.2019.02.004_bib65","doi-asserted-by":"crossref","first-page":"e72095","DOI":"10.1371\/journal.pone.0072095","article-title":"Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study","volume":"8","author":"Kjaersgaard","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clp.2019.02.004_bib66","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.4088\/JCP.15m10506","article-title":"Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy","volume":"77","author":"Newport","year":"2016","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib67","unstructured":"GalxoSmithKline. GSK pregnancy registry for Bupropioin. Available at: http:\/\/pregnancyregistry.gsk.com\/documents\/bup_report_final_2008.pdf. Accessed August 11, 2018."},{"key":"10.1016\/j.clp.2019.02.004_bib68","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ajog.2004.09.027","article-title":"Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study","volume":"192","author":"Chun-Fai-Chan","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib69","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/pds.1296","article-title":"Bupropion in pregnancy and the prevalence of congenital malformations","volume":"16","author":"Cole","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clp.2019.02.004_bib70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0447.2000.tb10945.x","article-title":"Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children\/adolescents and in the elderly","volume":"101","author":"Emslie","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clp.2019.02.004_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S003329171000022X","article-title":"Should we stop using tricyclic antidepressants in pregnancy?","volume":"41","author":"Pariante","year":"2011","journal-title":"Psychol Med"},{"key":"10.1016\/j.clp.2019.02.004_bib72","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4088\/JCP.09com05529","article-title":"No decision is without risk","volume":"70","author":"Suri","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.psc.2010.02.001","article-title":"Treatment of mood disorders during pregnancy and postpartum","volume":"33","author":"Cohen","year":"2010","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.clp.2019.02.004_bib74","article-title":"A\u00a0review of therapeutic uses of mirtazapine in psychiatric and medical conditions","volume":"15","author":"Alam","year":"2013","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.clp.2019.02.004_bib75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.euroneuro.2015.06.014","article-title":"Mirtazapine in pregnancy and lactation - a systematic review","volume":"26","author":"Smit","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clp.2019.02.004_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000698","article-title":"Low-dose mirtazapine in major depression developed after hyperemesis gravidarum: a case series","author":"Uguz","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.clp.2019.02.004_bib77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/070674370304800207","article-title":"A\u00a0multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy","volume":"48","author":"Einarson","year":"2003","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1176\/ajp.132.5.529","article-title":"Cardiovascular malformations with lithium use during pregnancy","volume":"132","author":"Weinstein","year":"1975","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib79","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1176\/appi.ajp.162.11.2162","article-title":"Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy","volume":"162","author":"Newport","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib80","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa1612222","article-title":"Lithium use in pregnancy and the risk of cardiac malformations","volume":"376","author":"Patorno","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib81","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1212\/01.wnl.0000304343.45104.d6","article-title":"Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy","volume":"70","author":"Holmes","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clp.2019.02.004_bib82","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e31821ccd18","article-title":"Final results from 18 years of the International lamotrigine pregnancy registry","volume":"76","author":"Cunnington","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clp.2019.02.004_bib83","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/WNL.0000000000002540","article-title":"Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies","volume":"86","author":"Dolk","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clp.2019.02.004_bib84","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.clp.2019.02.004_bib85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40263-017-0433-0","article-title":"Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-Analysis","volume":"31","author":"Pariente","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clp.2019.02.004_bib86","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/01.WNL.0000154516.43630.C5","article-title":"Increased rate of major malformations in offspring exposed to valproate during pregnancy","volume":"64","author":"Wyszynski","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clp.2019.02.004_bib87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clp.2019.02.004_bib88","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.yebeh.2013.08.001","article-title":"Fetal antiepileptic drug exposure: adaptive and emotional\/behavioral functioning at age 6 years","volume":"29","author":"Cohen","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clp.2019.02.004_bib89","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clp.2019.02.004_bib90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJM199103073241006","article-title":"Spina bifida in infants of women treated with carbamazepine during pregnancy","volume":"324","author":"Rosa","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib91","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.pra.0000351878.45260.94","article-title":"Use and safety of antipsychotic drugs during pregnancy","volume":"15","author":"Einarson","year":"2009","journal-title":"J\u00a0Psychiatr Pract"},{"key":"10.1016\/j.clp.2019.02.004_bib92","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/tera.1420150108","article-title":"Possible teratogenic effect of phenothiazines in human beings","volume":"15","author":"Rumeau-Rouquette","year":"1977","journal-title":"Teratology"},{"key":"10.1016\/j.clp.2019.02.004_bib94","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/088506668600100304","article-title":"Evaluation and treatment of agitation in the intensive care unit","volume":"1","author":"Tesar","year":"1986","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.clp.2019.02.004_bib95","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4088\/JCP.v66n0406","article-title":"Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study","volume":"66","author":"McKenna","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","article-title":"Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study","volume":"33","author":"Habermann","year":"2013","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clp.2019.02.004_bib97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1176\/appi.ajp.2015.15040506","article-title":"Reproductive safety of second-generation antipsychotics: current data from the Massachusetts general hospital national pregnancy registry for atypical antipsychotics","volume":"173","author":"Cohen","year":"2015","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.clp.2019.02.004_bib98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.schres.2016.07.023","article-title":"Risks associated with antipsychotic treatment in pregnancy: comparative cohort studies based on electronic health records","volume":"176","author":"Petersen","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clp.2019.02.004_bib99","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.12372","article-title":"Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review","volume":"116","author":"Ennis","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clp.2019.02.004_bib100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2393-14-242","article-title":"Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance","volume":"14","author":"Hanley","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.clp.2019.02.004_bib101","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(75)90548-6","article-title":"Association between cleft lip with or without cleft palate and prenatal exposure to diazepam","volume":"2","author":"Safra","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.clp.2019.02.004_bib102","doi-asserted-by":"crossref","first-page":"e100996","DOI":"10.1371\/journal.pone.0100996","article-title":"First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study","volume":"9","author":"Ban","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clp.2019.02.004_bib103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.genhosppsych.2012.09.003","article-title":"Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview","volume":"35","author":"Bellantuono","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib104","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1701-2163(16)34772-7","article-title":"The fetal safety of benzodiazepines: an updated meta-analysis","volume":"33","author":"Enato","year":"2011","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.clp.2019.02.004_bib105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.genhosppsych.2018.05.010","article-title":"Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders","volume":"53","author":"Freeman","year":"2018","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib106","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamapsychiatry.2017.2733","article-title":"Association of panic disorder, generalized anxiety disorder, and benzodiazepine treatment during pregnancy with risk of adverse birth outcomes","volume":"74","author":"Yonkers","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib107","first-page":"34S","article-title":"Neonatal apnea associated with maternal clonazepam therapy: a case report","volume":"66","author":"Fisher","year":"1985","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib108","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.282.6270.1106","article-title":"Effect of maternal lorazepam on the neonate","volume":"282","author":"Whitelaw","year":"1981","journal-title":"Br Med J"},{"key":"10.1016\/j.clp.2019.02.004_bib109","first-page":"289","article-title":"Postpartum course in women with preexisting panic disorder","volume":"55","author":"Cohen","year":"1994","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib110","first-page":"156","article-title":"Postpartum obsessive compulsive disorder: a case series","volume":"54","author":"Sichel","year":"1993","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clp.2019.02.004_bib111","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000056242","article-title":"Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series","volume":"70","author":"Weinstock","year":"2001","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.clp.2019.02.004_bib112","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1212\/WNL.0b013e31828f18c1","article-title":"Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study","volume":"80","author":"Fujii","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.clp.2019.02.004_bib113","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejogrb.2014.08.013","article-title":"Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy","volume":"181","author":"Guttuso","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.clp.2019.02.004_bib114","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1081-1206(10)63385-6","article-title":"Prospective controlled study of hydroxyzine and cetirizine in pregnancy","volume":"78","author":"Einarson","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clp.2019.02.004_bib115","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-0747","article-title":"Perinatal outcomes after treatment with ADHD medication during pregnancy","volume":"140","author":"N\u00f6rby","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.clp.2019.02.004_bib116","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/GRF.0000000000000098","article-title":"Caring for opioid-dependent pregnant women: prenatal and postpartum care considerations","volume":"58","author":"Krans","year":"2015","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib117","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cct.2014.08.009","article-title":"Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome","volume":"39","author":"Winhusen","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clp.2019.02.004_bib118","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0b013e318256496e","article-title":"ACOG committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy","volume":"119","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clp.2019.02.004_bib119","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2019.02.004_bib120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","article-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study","volume":"101","author":"Fischer","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.clp.2019.02.004_bib121","doi-asserted-by":"crossref","first-page":"j3326","DOI":"10.1136\/bmj.j3326","article-title":"Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study","volume":"358","author":"Huybrechts","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.clp.2019.02.004_bib122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pmedr.2017.12.010","article-title":"Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014","volume":"9","author":"Hirschtritt","year":"2018","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.clp.2019.02.004_bib123","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes","volume":"132","author":"Schuman-Olivier","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clp.2019.02.004_bib124","unstructured":"National practice guideline. Available at: https:\/\/www.asam.org\/resources\/guidelines-and-consensus-documents\/npg. Accessed August 22, 2018."},{"key":"10.1016\/j.clp.2019.02.004_bib125","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1345\/aph.1P279","article-title":"Nicotine replacement therapy effect on pregnancy outcomes","volume":"44","author":"Forinash","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clp.2019.02.004_bib126","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1097\/AOG.0000000000002353","article-title":"ACOG committee opinion no. 721. Smoking cessation during pregnancy","volume":"130","year":"2017","journal-title":"Obstet Gynecol"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510819300119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510819300119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:56:35Z","timestamp":1758815795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510819300119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0095510819300119"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2019.02.004","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Psychotropic Medications During Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}